Tuesday, November 24, 2009, 11:25pm EST - Canadian Markets are closed.
To create a watchlist or portfolio of shares, Sign-in or Register

Alexza Pharmaceuticals Inc. (ALXA)

 At 15:59 EST: 2.31 USD  Up 0.07 (3.03%)  
MORE ON ALXA
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Alexza Pharmaceuticals, Inc. (NGM:ALXA) Delayed quote dataEdit
Last Trade: 2.31 USD
Trade Time: 3:59PM EST
Change: Up 0.07 (3.03%)
Prev Close: 2.24
Open: 2.23
Bid: 1.39 x 100
Ask: 3.20 x 100
1y Target Est: 15.00
Day's Range: 2.17 - 2.31
52wk Range: 1.30 - 3.53
Volume: 61,803
Avg Vol (3m): 113,689
Market Cap: 119.23M
P/E (ttm): N/A
EPS (ttm): -1.63
Div & Yield: N/A (N/A%)
Alexza Pharmaceuticals Inc. (ALXA)
1d  5d  3m  6m  1y  2y  5y 
 Add ALXA to Portfolio   Download Data

HEADLINES
• Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
PRNewswire (Thu, Nov 19)
• ALEXZA PHARMACEUTICALS INC. Financials
EDGAR Online Financials (Sat, Nov 14)
• Alexza Pharmaceuticals CEO Interview With The Wall Street Transcript
Wall Street Transcript (Wed, Nov 11)
• Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call Transcript
at Seeking Alpha (Mon, Nov 9)
• Alexza Pharmaceuticals Inc. Earnings Call scheduled for 5:00 pm ET today
CCBN (Mon, Nov 9)
• ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Mon, Nov 9)
• Alexza Reports 2009 Third Quarter Financial Results and Updates AZ-004 (Staccato(R) Loxapine) NDA Status Conference Call Scheduled for Today - Monday
PRNewswire (Mon, Nov 9)
• Q3 2009 ALEXZA PHARMACEUTICALS INC Earnings Release - After Market Close
CCBN (Mon, Nov 9)
• Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 Conference Call Scheduled for Mo
PRNewswire (Mon, Nov 2)
• ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
EDGAR Online (Mon, Nov 2)
More Headlines for ALXA...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Alexza Pharmaceuticals, Inc., a development stage company, focuses on the development and commercialization of products for the treatment of acute and intermittent conditions primarily in the United States.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices